What is AccessHope?
Headquartered in Duarte, California, AccessHope operates as a specialized healthcare services organization dedicated to optimizing cancer treatment pathways. Founded in 2019, the company functions as a vital link between employees facing cancer diagnoses and subspecialists at National Cancer Institute-designated comprehensive cancer centers. Through strategic partnerships with prestigious institutions such as the Dana-Farber Cancer Institute, Johns Hopkins Medicine, and Northwestern Medicine, AccessHope provides remote oncology insights. This approach allows patients to receive advanced clinical guidance without the logistical burden of changing their primary treating oncologists or traveling long distances, effectively democratizing access to elite medical knowledge.
The company's market position is defined by its ability to integrate seamlessly into existing employer-sponsored health plans, providing a scalable solution that improves patient outcomes while managing the complexities of modern oncology. By focusing on collaborative care, AccessHope addresses the critical need for precision medicine in a fragmented healthcare environment.
How much funding has AccessHope raised?
AccessHope has raised a total of $33M across 1 funding round:
Series B
$33M
Series B (2024): $33M with participation from City of Hope
Key Investors in AccessHope
City of Hope
City of Hope is a premier National Cancer Institute-designated comprehensive cancer center that integrates clinical care, research, and education to advance the standard of oncology treatment.
What's next for AccessHope?
With the successful completion of this major enterprise-level funding, AccessHope is well-positioned to accelerate its growth trajectory and expand its network of institutional partners. The strategic allocation of this capital will likely focus on enhancing the digital infrastructure required to support remote oncology consultations and broadening the reach of its services to a larger employer base. As the organization matures, it is expected to further refine its clinical decision-support tools, ensuring that the latest research from top-tier cancer centers is accessible to patients regardless of their geographic location. This phase of development marks a transition from initial service deployment to widespread enterprise adoption, reinforcing the company's role as a leader in the intersection of oncology and health technology.
See full AccessHope company page
